Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
3
50%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 42 (33.3%)

Trials by Status

withdrawn117%
completed467%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_4

A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

NCT07053345
completedphase_2

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
completedphase_3

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
completedphase_3

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

NCT04338321
withdrawnphase_3

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

NCT03852160
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07053345Phase 4

A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

Recruiting
NCT01998958Phase 2

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

Completed
NCT03434041Phase 3

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Completed
NCT04338321Phase 3

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

Completed
NCT03852160Phase 3

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Withdrawn
NCT04599855Phase 4

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6